This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Microbial integrity testing for preservative-free drug formulations
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Interview with Guillaume Brouet on Aptar Pharma Services
Publications, Pharmaceutical, Innovation & Insights
Aptar Pharma provides guidance on FDA regulatory framework for OINDPs
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
Connected Medicine: Insights from Payers and Other Stakeholders
Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations